Clinical and microbiological epidemiology of Candida infections in a high-complexity hospital in Tolima, Colombia (2014–2024) Authors: Rafael A. Ramírez-Trujillo, Paula Carvajal-Hernández, Ángel González, Theerapong Krajaejun, Theerapong Krajaejun, Theerapong Krajaejun, Theerapong Krajaejun Published: 2026 ABSTRACT BackgroundCandida spp. infections are an increasing challenge in high-complexity hospitals, yet epidemiological data remain scarce in underrepresented in Colombian regions such as Tolima.MethodsWe conducted a retrospective observational study in a high-complexity hospital in Ibagué (Tolima, Colombia) from 2014 to 2024, integrating two institutional data sources: administrative/clinical records and the microbiology laboratory database (WHONET). Species identification relied on culture and VITEK, and antifungal susceptibility was interpreted using criteria from the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST). We summarized data using frequencies/proportions and medians (IQR), explored patterns with multiple correspondence analysis (MCA), and estimated associations with candidemia using penalized multivariable logistic regression due to low event frequency.ResultsWe identified 987 candidiasis episodes and 776 fungal isolates, of which 314 were Candida (40.46%). Mucocutaneous disease predominated (vulvovaginal 50.7%; oropharyngeal 24.3%), while candidemia represented 2.0% of episodes. Among isolates, Candida albicans was most frequent (58.9%), followed by C. parapsilosis (16.6%), C. tropicalis (12.1%), and Nakaseomyces glabratus (6.4%); Candida auris was detected once. In exploratory clinical/administrative models, clinically recorded candidemia showed associations with invasive devices (OR 5.54, 95% CI 2.01–15.64), recent surgery (OR 7.11, 95% CI 1.20–30.88) and tumor (OR 19.88, 95% CI 3.14–97.51). Susceptibility data were available for 196/314 isolates (62.4%); echinocandin activity was high, whereas azole susceptibility was more variable.ConclusionsCandidiasis showed a sustained recorded burden and substantial non-albicans diversity, supporting local surveillance, species-level identification, and isolate-level susceptibility testing. Introduction Fungal infections (FIs) are an increasing public health problem, causing 1.5 million deaths annually, a burden comparable to tuberculosis or malaria [1]. This rise reflects expanding vulnerable populations (e.g., diabetes, untreated HIV, cancer, transplantation, immunosuppressive therapies) and healthcare exposures in critically ill patients, including broad-spectrum antibiotics and invasive devices [2]. Candida spp., commensal yeasts, can act opportunistically, producing disease from superficial mucocutaneous infection to invasive candidiasis and candidemia, a frequent cause of hospital-acquired sepsis, particularly in intensive care units (ICUs) [3,4]. Globally, a shift toward non-albicans species and variable antifungal susceptibility complicates empiric therapy and may worsen outcomes [5]. In 2022, the World Health Organization (WHO) issued its first list of priority fungal pathogens, highlighting C. auris and C. albicans as critical and Nakaseomyces glabratus, C. tropicalis, and C. parapsilosis as high-priority pathogens. Despite surveillance initiatives in several regions, data in Latin America and especially Colombia, remain limited and fragmented, with underreporting exacerbated by the absence of mandatory notification for most fungal diseases [2,6]. Recent actions led by the Colombian National Institute of Health (INS), including the incorporation of C. auris into Colombia’s National Public Health Surveillance System (SIVIGILA, for its Spanish acronym), the updating of national guidelines, and laboratory surveillance criteria for Candida spp. isolates recovered from healthcare-associated infections (HAIs; IAAS in Spanish) or showing antifungal resistance profiles, represent important progress in fungal disease surveillance; however, implementation and data availability remain incomplete [7]. In Tolima, evidence on local prevalence, species distribution, and resistance patterns of Candida spp. is scarce relative to other Colombian regions [2,8], limiting data-driven decisions and detection of temporal changes or intrahospital events [9,10]. Therefore, this single-center study aimed to evaluate the epidemiology, species distribution, exploratory associated factors, and antifungal susceptibility profiles of Candida infections at a high-complexity referral hospital in Ibagué, Tolima, Colombia, spanning a ten-year period (2014–2024). Methodology Design and setting An observational, retrospective descriptive-analytical study was conducted in a high-complexity hospital in Ibagué, Tolima, Colombia, between 2014 and 2024. Two institutional data sources from the same participating hospital were used: (A) a clinical/administrative database derived from hospital administrative and clinical records, and (B) a microbiological database derived from Microbiology Laboratory records. Although both sources came from the same physical institution, they were generated through separate institutional information workflows and were not linked record by record for this retrospective study. The primary scope of the study was the overall clinical and microbiological burden of Candida infections, including mucocutaneous, localized, invasive, and bloodstream presentations, rather than candidemia alone. MIC-based susceptibility analyses were restricted to 2022–2024, the period with structured MIC exports in WHONET format. The clinical/administrative database was used to describe clinically recorded candidiasis episodes and to explore factors associated with candidemia and invasive candidiasis, whereas the microbiological database was used to describe Candida spp. isolates, specimen sources, species distribution, antifungal susceptibility, and factors associated with non-albicans isolation. Selection-stage counts and data access details are provided in (S1 Text). Data were accessed for research purposes on 2 August 2025 for the clinical/administrative database and on 9 August 2025 for the microbiological database. This study is reported in accordance with the STROBE statement and the RECORD extension for routinely collected health data; completed checklists are available as Supporting Information (S1 Checklist). Population, definitions, and selection Patients with a clinical diagnosis of candidiasis and/or microbiological identification of Candida spp. were included. The unit of analysis was an infection episode/record in the hospital database and an isolate record in the laboratory database. Exact duplicates were removed within each database; no additional time-window deduplication was applied. Records without clinical or microbiological corroboration, contaminated samples, or missing key variables were excluded. Clinical forms were classified using the recorded clinical/administrative diagnosis and ICD-10 coding (S1 Table). Cases were grouped as mucocutaneous/localized non-invasive candidiasis, candidemia, deep-seated non-candidemic invasive candidiasis, or other/unspecified candidiasis. Deep-seated non-candidemic invasive candidiasis included organ-specific invasive records without recorded candidemia, including CNS involvement/meningitis. Combined or disseminated candidiasis was not assigned as a separate category because it was not documented in the clinical/administrative diagnosis fields. For suspected invasive fungal infection, EORTC/MSG categories (proven/probable/possible) were applied when appropriate. Isolation, identification, and susceptibility Clinical samples were processed by the institution’s Microbiology Laboratory as part of routine care. Candida spp. were identified using routine laboratory methods, including conventional culture and/or BD Phoenix during 2014–2021 and the VITEK 2 Compact system during 2022–2024. During the VITEK 2 Compact period, yeast identification was performed using the YST card, and antifungal susceptibility testing was performed using the AST-YS08 card. WHONET MIC data exports (µg/mL) included amphotericin B, fluconazole, voriconazole, caspofungin, micafungin, and flucytosine (5-FC). MICs were interpreted using current CLSI guidance (S/I/R) when breakpoints were available. Because clinical breakpoints are not available for 5-FC for several species, 5-FC was analyzed exclusively using EUCAST ECOFF classification and reported as wild-type (WT) or non-wild-type (NWT), as described in [11] (S2 Table, S2 Text). To avoid overinterpretation, 5-FC results are reported separately in S6 Table. Isolates without MIC results for a given antifungal were excluded from that antifungal-specific analysis (S3 Table). Statistical analysis Data were prepared, cleaned, coded, and managed in Microsoft Excel before statistical analysis. All statistical analyses were performed using R software, version 4.4.2. Categorical variables were summarized as n (%) and continuous variables as median (IQR). Group comparisons used χ² tests and non-parametric tests; two-sided p value <0.05 was considered significant. Multiple correspondence analysis (MCA) was applied to selected categorical variables defined a priori. Logistic regression estimated odds ratios (ORs) and 95% confidence intervals (CIs); Firth-penalized logistic regression was used for candidemia (infrequent outcome), and standard logistic regression for invasive candidiasis and the non-albicans outcome. Age was categorized as <27 vs ≥ 27 years, and length of stay as 1–3, 4–10, and ≥11 days (reference: ≥ 11). Missing data were handled by reporting variable-specific denominators; regression models used complete-case analysis. Regression models were exploratory and data-source specific: candidemia and invasive candidiasis models used the clinical/administrative database, whereas the non-albicans model used microbiological isolate records. Because the databases were not linked record by record, these models were not interpreted as patient-level clinical–microbiological risk models. Ethics statement The research ethics committee of the participating institution approved this study (Acta 116, 24 January 2025). This retrospective study used secondary clinical and microbiological records obtained under restricted institutional access. For public sharing, only de-identified datasets without direct personal identifiers or sensitive institutional variables were deposited in Zenodo. The study was conducted in accordance with the Declaration of Helsinki, CIOMS guidelines, and applicable Colombian regulations, including Resolution 8430 of 1993 for research without risk and provisions regarding the management of medical records. The requirement for informed consent was waived by the ethics committee because the study used retrospective, de-identified data. No animal studies were performed. Results Institutional burden and temporal trend (2014–2024) During 2014–2024, the hospital administrative database included 243,013 cumulative institutional care records across different service locations. This administrative denominator should not be interpreted as a count of unique patients. The clinical database identified 987 episodes compatible with candidiasis, corresponding to a recorded candidiasis burden of 0.41% (4.06 per 1,000 institutional care records). Annual rates ranged from 0.22% to 0.61%, peaking in 2018 (n = 147) and decreasing thereafter, while cumulative counts increased over time (Fig 1A). Temporal trend and cumulative counts of clinically recorded candidiasis episodes and microbiologically confirmed Candida isolate records, 2014–2024. (A) Probable candidiasis episodes recorded in the hospital clinical/administrative database. (B) Microbiologically confirmed Candida spp. isolate records from the laboratory database. In both panels, bars and their numeric labels represent annual counts, whereas the line and its numeric labels represent cumulative counts over time. In the microbiological database, 776 fungal/yeast isolate records were available, of which 314 were Candida spp. (40.46%, 314/776). Because laboratory data are recorded as isolates, counts may exceed clinical episodes due to repeat cultures. Cumulative confirmed isolates increased over time (Fig 1B). Clinical spectrum and population characteristics (clinical database; n=987) The clinical spectrum was dominated by mucocutaneous disease: vulvovaginal candidiasis 50.66% (n = 500) and oropharyngeal candidiasis 24.32% (n = 240). Other categories included unspecified candidiasis 11.96% (n = 118), deep-seated non-candidemic invasive candidiasis 8.21% (n = 81), and candidemia 2.03% (n = 20) (Fig 2). The other/unspecified group (n = 146) mainly reflected unspecified candidiasis records (n = 118) and should be interpreted as evidence of limited diagnostic granularity in the retrospective clinical/administrative database rather than as a distinct clinical syndrome. Operational classification of clinically recorded candidiasis episodes, 2014–2024. IC, invasive candidiasis; CNS, central nervous system. Deep-seated non-candidemic IC comprised organ-specific invasive records, including CNS involvement/meningitis. Overall, 77.81% of episodes occurred in women (F:M 3.5:1), largely driven by vulvovaginal candidiasis. Excluding this category, oropharyngeal candidiasis remained more frequent in women (61.25%) than men (38.75%). Median age was 29 years (IQR 22–53); 28 years in women (IQR 22–44) and 39 years in men (IQR 8–69). Oropharyngeal candidiasis showed a bimodal distribution, with 32.9% in early childhood (79/240) and 35.8% in those ≥60 years (86/240). Age differed by infection type (p < 0.001), with higher medians in invasive forms, including candidemia (38 years, IQR 28–70) and other organ-specific invasive records (46 years, IQR 30–77), than in vulvovaginal candidiasis (27 years, IQR 24–34) (Fig 3A). Age also differed by care setting (p < 0.001), with higher medians in critical care (coronary ICU 69 years; adult ICU 57 years) and lower medians in obstetrics (26 years) and neonatal ICU (1 year) (Fig 3B). Length of stay differed by infection type (p < 0.001), with longer stays for candidemia and deep-seated non-candidemic invasive candidiasis, including CNS involvement/meningitis, than for mucocutaneous/non-invasive forms. By service, length of stay was largely explained by care setting (η² = 0.51; p < 0.001), with longer stays in ICU and general wards (Table 1). 10.1371/journal.pone.0354684.t001Table 1Sociodemographic, clinical, and care-related characteristics of candidiasis episodes (suspected/probable) (n = 987) in a high-complexity hospital in Tolima, Colombia (2014–2024).VariableCategoriesn% Sex Female76877.81Male21922.19 Age group Early childhood (0–5 years)10110.23Childhood (6–11 years)353.55Adolescence (12–18 years)343.44Youth (19–26 years)23924.21Adulthood (27–59 years)37237.69Older adult (≥60 years)20620.87 Hospital location / care setting ICU (adult)80.81ICU (neonatal)80.81ICU (coronary)60.61Emergency department67368.19Hospitalization18018.24Surgery303.04Obstetrics828.31 Length of hospital stay Short (1–3 days)85386.42Medium (4–10 days)858.61Prolonged (11–30 days)373,75Extended (>31 days)121,22 Type of infection Candidemia202.03CNS involvement/meningitis40.41Other organ-specific invasive records777.80HIV-associated opportunistic80.81Mucocutaneous oropharyngeal24024.32Urinary101.01Vulvovaginal candidiasis50050.66Cutaneous/nail candidiasis101.01Unspecified candidiasis11811.96 Comorbidities Neoplasia / tumor111.11Diabetes mellitus313.14Gastrointestinal disease515.17Respiratory dysfunction505.07Cardiovascular disease121.22Arterial hypertension101.01Urinary tract infection404.05Threatened abortion282.84Invasive devices12512.66Note: Comorbidities are not mutually exclusive; therefore, percentages do not sum to 100%. Percentages were calculated using n = 987 as the denominator, unless otherwise specified due to missing data or not determined (ND) values. Sociodemographic, clinical, and care-related characteristics of candidiasis episodes (suspected/probable) (n = 987) in a high-complexity hospital in Tolima, Colombia (2014–2024). Note: Comorbidities are not mutually exclusive; therefore, percentages do not sum to 100%. Percentages were calculated using n = 987 as the denominator, unless otherwise specified due to missing data or not determined (ND) values. Age distribution according to A) type of Candida infection and B) hospital care setting, with statistical significance indicated where applicable. Species distribution, sample origin, and patterns by service (microbiological database; n = 314) The time series showed a transition toward greater diversity, with non-albicans species proportions of approximately 41.2% (in 2023) and 43.0% (in 2024), and the detection of C. auris in 2023, highlighting the need for surveillance of emerging species (Fig 4A). By service, C. albicans predominated in outpatient and lower-complexity settings (outpatient clinic and emergency department), while non-albicans species were more prevalent in critical care areas. C. parapsilosis was reported as the only species in the neonatal ICU (n = 3) (Fig 4B). Proportional distribution of Candida spp. isolates (n = 314) according to A) year, B) hospital service/care setting, and C) clinical specimen source. Bars show category-specific percentages (100% stacked bars); the number of isolates (n) is indicated within each bar. Among confirmed isolates, C. albicans was the predominant species (58.92%; n = 185). Non-albicans species accounted for 41.08%, including C. parapsilosis (16.56%; n = 52), C. tropicalis (12.10%; n = 38), and Nakaseomyces glabratus (6.37%; n = 20). Less frequent species were detected, including C. dubliniensis (n = 6), Wickerhamomyces anomalus (n = 4), and C. auris (n = 1), in addition to other rare isolates. The anatomical origin was concentrated in superficial tissues/cutaneous appendages (36.62%; n = 115) and urine (33.44%; n = 105). Blood samples constituted 7.32% (n = 23), followed by lower respiratory tract 6.05% (n = 19) and surgical site/soft tissue 5.73% (n = 18) (Fig 4C). These 23 microbiological blood-isolate records were not linked record by record to the 20 clinical/administrative candidemia records; therefore, both counts should be interpreted as complementary indicators from separate institutional information workflows rather than matched events. In the bloodstream subgroup (n = 23), the etiology was heterogeneous: C. albicans 39.13%, C. parapsilosis 34.78%, W. anomalus 13.04%, N. glabratus 8.70%, and C. auris 4.35%, highlighting the diversity in invasive origin (Fig 4C). Age also varied by species (p = 0.0168), with higher medians in species of greater clinical relevance (C. albicans 60 years; C. tropicalis 70 years; N. glabratus 68 years; C. parapsilosis 57 years). Associated factors (Multivariate models) Multiple correspondence analysis (MCA) was used as an exploratory approach to summarize co-occurrence patterns among categorical variables in the hospital/clinical database. The first two dimensions explained 9.1% (Dim1) and 7.7% (Dim2) of inertia (16.8% cumulative) and showed separation between invasive and mucocutaneous presentations: candidemia clustered with higher-complexity care, invasive procedures/devices, and blood samples, whereas mucocutaneous forms clustered with lower-complexity profiles (Fig 5A; S4 Table, S5 Table). Multiple correspondence analysis (MCA) of Candida infection types according to data source. A) Hospital/clinical database, B) Microbiological/laboratory database. A second MCA based on microbiological isolate records incorporated clinical syndrome, sample origin, species, and available susceptibility interpretation categories. The first two dimensions explained 11.4% (Dim1) and 7.3% (Dim2) of inertia (18.7% cumulative). Candidemia clustered with blood samples and tracheal aspirate, while deep-seated non-candidemic invasive candidiasis clustered with sterile fluids; vulvovaginal candidiasis clustered mainly with C. albicans, C. tropicalis and N. glabratus and with vaginal/urinary samples (Fig 5B; S4 Table, S5 Table). Overall, MCA findings were interpreted descriptively and used to inform subsequent comparisons and regression modeling. Exploratory multivariable models identified data-source-specific associations (Table 2). In the clinical/administrative database, clinically recorded candidemia showed an inverse association with short hospital stay (OR = 0.04; 95% CI: 0.01–0.14), whereas positive associations were observed with respiratory dysfunction (OR = 4.76; 95% CI: 1.23–16.39), invasive devices (OR = 5.54; 95% CI: 1.99–15.64), surgery (OR = 7.11; 95% CI: 1.201–30.87), and tumor (OR = 19.88; 95% CI: 3.13–97.51). 10.1371/journal.pone.0354684.t002Table 2Exploratory multivariable logistic regression models for candidemia, invasive candidiasis, and non-albicans isolation (vs C. albicans).VariableORIC 95%p-valueEffect Candidemia ––<0.001p value (LR test)Short hospital stay0.04(0.01 - 0.14)<0.001Inverse associationRespiratory dysfunction4.76(1.23 - 16.39)0.025Associated factorInvasive devices5.54(1.99 - 15.64)0.001Associated factorSurgery7.11(1.20 - 30.87)0.033Associated factorTumor19.88(3.13 - 97.51)0.003Associated factor Invasive candidiasis ––<0.001p value (LR test)Age > 27 years2.73(1.61 - 4.85)0.003Associated factorMale sex4.98(3.15 - 7.91)<0.001Associated factorCardiovascular disease5.67(1.41 - 18.91)0.007Associated factorTumor9.51(2.51 - 37.23)0.0008Associated factor Non-albicans ––0.004p value (LR test)Candidemia3.02(1.04 - 9.23)0.045Associated factorAge > 27 years3.63(1.39 - 11.48)0.014Associated factorUrinary source1.78(1.04 - 3.04)0.033Associated factorNote: Adjusted ORs (95% CI) from exploratory multivariable logistic regression models. For candidemia, Firth penalized logistic regression was used due to the low event frequency. For invasive candidiasis and non-albicans isolation, standard logistic regression was applied. Model-specific sample sizes were: candidemia model, n = 987, events = 20; invasive candidiasis model, n = 987, events = 101; non-albicans isolation model, n = 314, events = 129. Exploratory multivariable logistic regression models for candidemia, invasive candidiasis, and non-albicans isolation (vs C. albicans). Note: Adjusted ORs (95% CI) from exploratory multivariable logistic regression models. For candidemia, Firth penalized logistic regression was used due to the low event frequency. For invasive candidiasis and non-albicans isolation, standard logistic regression was applied. Model-specific sample sizes were: candidemia model, n = 987, events = 20; invasive candidiasis model, n = 987, events = 101; non-albicans isolation model, n = 314, events = 129. For invasive candidiasis, exploratory associations were observed with age > 27 years (OR = 2.73; 95% CI: 1.61–4.85), male sex (OR = 4.98; 95% CI: 3.15–7.91), cardiovascular disease (OR = 5.67; 95% CI: 1.41–18.91), and tumor (OR = 9.51; 95% CI: 2.51–37.23). In the microbiological isolate-level model, non-albicans isolation (vs C. albicans) showed associations with candidemia (OR = 3.02; 95% CI: 1.04–9.23), age > 27 years (OR = 3.63; 95% CI: 1.392–11.483), and urinary source (OR = 1.78; 95% CI: 1.04–3.04). These findings should be interpreted as exploratory associations within their respective data sources. Antifungal Susceptibility (Isolates with Available MIC) Susceptibility testing was not available for all isolates; therefore, analyses were performed using isolates with recorded MICs, reporting denominators by species and antifungal agent (Table 3). In general, high activity of echinocandins (caspofungin and micafungin) was observed, with greater variability among azoles, particularly fluconazole. Five-fluorocytosine results were interpreted descriptively using EUCAST ECOFF-based WT/NWT categories and are reported separately in S6 Table to avoid confusion with clinical S/I/R interpretations. Species-specific denominators were uneven, and several species had fewer than 30 isolates; therefore, susceptibility percentages for low-frequency species should be interpreted descriptively as isolate-level surveillance signals rather than as representative institutional resistance rates or cumulative susceptibility estimates. No repeated de-identified medical-record codes were detected among the 196 AFST records. Because (Table 3) pools isolates from heterogeneous clinical sources, including superficial, urogenital, and bloodstream samples, these data should be viewed as a general microbiological survey and should not be used alone to guide empiric therapy for invasive candidiasis. 10.1371/journal.pone.0354684.t003Table 3Antifungal susceptibility profile of Candida species with available MICs according to clinically interpretable categories (S, SDD, I, R).Candida spp.Antifungal agentS n (%)SDD n (%)I n (%)R n (%)Total n (%) Candida albicans Fluconazole96(89.71)3(2.80)–8(7.47)107(100)Voriconazole103(96.27)––4(3.73)107(100)Caspofungin102(95.33)–3(2.80)2(1.87)107(100)Micafungin100(93.46)–3(2.80)4(3.74)107(100) Candida tropicalis Fluconazole33(97.05)––1(2.95)34(100)Voriconazole33(97.05)––1(2.95)34(100)Caspofungin34(100)–––34(100)Micafungin34(100)–––34(100) Candida parapsilosis Fluconazole23(85.19)1(3.70)–3(11.11)27(100)Voriconazole24(88.90)–2(7.40)1(3.70)27(100)Caspofungin26(96.30)–1(3.70)–27(100)Micafungin27(100)–––27(100) Nakaseomyces glabratus Fluconazole––––– (C. glabrata) Voriconazole13(68.42)–6(31.57)–19(100)Caspofungin–––––Micafungin18(94.74)––1(5.26)19(100) Candidozyma haemuli Fluconazole–––1(100)1(100) (Candida haemulonii) Voriconazole1(100)–––1(100)Caspofungin––1(100)–1(100)Micafungin––––– Candida dubliniensis Fluconazole1(25.00)––3(75.00)4(100)Voriconazole3(75.00)––1(25.00)4(100)Caspofungin3(100)–––3(100)Micafungin––––– Meyerozyma guilliermondii Fluconazole1(100)–––1(100) (C. guilliermondii) Voriconazole1(100)–––1(100)Caspofungin1(100)–––1(100)Micafungin1(100)–––1(100) Wickerhamomyces anomalus Fluconazole3(100)–––3(100) (C. pelliculosa) Voriconazole––2(66.66)1(33.33)3(100)Caspofungin2(66.66)––1(33.33)3(100)Micafungin–––––Note: S, susceptible; SDD, susceptible dose-dependent; I, intermediate; R, resistant. 5-FC results are reported separately in Table S6. Species with fewer than 30 isolates are reported descriptively and should be interpreted as isolate-level surveillance signals rather than representative institutional resistance rates or cumulative susceptibility estimates. AFST analyses were performed at the isolate-record level; no repeated de-identified medical-record codes were detected among the 196 AFST records. Because this table pools isolates from heterogeneous clinical sources, including superficial, urogenital, and bloodstream samples, it should be interpreted as a general microbiological survey and not as a standalone guide for empiric therapy in invasive candidiasis. Antifungal susceptibility profile of Candida species with available MICs according to clinically interpretable categories (S, SDD, I, R). Note: S, susceptible; SDD, susceptible dose-dependent; I, intermediate; R, resistant. 5-FC results are reported separately in Table S6. Species with fewer than 30 isolates are reported descriptively and should be interpreted as isolate-level surveillance signals rather than representative institutional resistance rates or cumulative susceptibility estimates. AFST analyses were performed at the isolate-record level; no repeated de-identified medical-record codes were detected among the 196 AFST records. Because this table pools isolates from heterogeneous clinical sources, including superficial, urogenital, and bloodstream samples, it should be interpreted as a general microbiological survey and not as a standalone guide for empiric therapy in invasive candidiasis. In C. albicans (n = 107), fluconazole showed 89.71% susceptibility, with 7.47% resistance, and voriconazole 96.27% susceptibility; caspofungin and micafungin showed >93% susceptibility. In C. tropicalis (n = 34), fluconazole and voriconazole reached 97.05% susceptibility, and echinocandins 100%. In C. parapsilosis (n = 27), fluconazole showed lower performance (S 85.19%; R 11.11%) compared to echinocandins, and micafungin remained 100% susceptible. In N. glabratus (n = 19), a more limited profile was observed, with preserved susceptibility to micafungin (94.74%) and a higher proportion in the intermediate category for voriconazole. Discussion In this retrospective study (2014–2024), the recorded candidiasis burden was 0.41% (4.06 cases per 1000 institutional care records). Although low in absolute terms, this represents a sustained burden for a high-complexity hospital and is consistent with ranges reported in Latin American institutions with comparable care profiles [1,12,13]. In Colombia, reference hospital series have described similar magnitudes, suggesting that this behavior is not isolated and providing a baseline for a region with historically limited evidence [4,14]. The main contribution of this work is the longitudinal characterization and the combined clinical–microbiological perspective to support local surveillance and decision-making. The low recorded candidemia rate should be interpreted cautiously. Candidemia represented a small subset of the overall Candida infection burden captured in this study, whereas the main analysis included all clinically recorded candidiasis forms. Because candidemia identification in the clinical/administrative database depended on retrospective diagnostic coding and was not linked record by record to laboratory-confirmed bloodstream isolates, the recorded rate may underestimate the true invasive disease burden. Consequently, the candidemia model should be interpreted as an exploratory analysis based on clinically recorded administrative data rather than as a definitive patient-level clinical–microbiological inference. The temporal pattern showed increasing diagnoses up to 2018 followed by a decline. During the 2018–2019 period, the hospital did not change its information software, and no shift from ICD-9 to ICD-10 coding occurred. Therefore, this pattern should not be attributed to a documented change in the Hospital Information System or coding system. However, as a record-based retrospective analysis, trends should be interpreted cautiously because changes in clinical awareness, diagnostic capacity, sampling practices, coding intensity, infection control measures, or antimicrobial optimization initiatives may influence case capture without necessarily reflecting true changes in incidence [15–17]. The key finding is the persistence of candidiasis across the decade, with cumulative burden over time. From a microbiological perspective, Candida spp. comprised 40.46% of fungal isolates, consistent with clinical laboratory reports where Candida constitutes a substantial fraction of isolated fungi and remains a leading agent of healthcare-associated mycoses [18–20]. The gap between clinical diagnoses and laboratory-confirmed isolates is expected, as many mucocutaneous infections are diagnosed and treated empirically without systematic microbiological confirmation [21,22]. Rather than a limitation, this highlights the need to standardize clinical definitions and to prioritize microbiological confirmation when management is likely to change (invasive disease, recurrences, or treatment failure). The 2014–2024 period also captures a transition in institutional microbiological capacity. Earlier years relied mainly on routine clinical and laboratory records with more limited microbiological granularity, whereas later years incorporated automated identification and susceptibility testing and structured WHONET MIC exports. This transition likely improved species-level identification, MIC availability, data standardization, and detection of less frequent or emerging species, supporting the value of the longitudinal design while reinforcing the need for cautious interpretation of comparisons across years. Clinically, mucocutaneous disease predominated, particularly vulvovaginal and oropharyngeal candidiasis, consistent with global epidemiology and the expected burden in women of reproductive age [23,24]. The relatively large other/unspecified category represents an important limitation of this retrospective record-based study. It reflects limited diagnostic granularity in clinical/administrative coding and may have led to misclassification or under-recognition of more specific clinical forms, particularly when the anatomical site or invasive status was not clearly documented. Although invasive forms were less frequent, their impact is disproportionate: candidemia and deep-seated invasive candidiasis are associated with higher severity, longer hospital stays, and increased resource use in international and regional cohorts [25,26]. The longer stays observed in candidemia and deep-seated non-candidemic invasive candidiasis, including CNS involvement/meningitis, align with this clinical pattern and support reporting outcomes separately for mucocutaneous/non-invasive versus invasive presentations [27]. For oropharyngeal candidiasis, concentration in early childhood and in those aged ≥60 years may indicate vulnerability and frailty across services rather than only classic severe immunosuppression [28]. In terms of species distribution, C. albicans remained the predominant species, which is consistent with its recognized role as a major etiologic agent of mucocutaneous candidiasis and hospital-associated Candida infections. This predominance was expected in our dataset because the clinical spectrum was dominated by mucocutaneous disease, particularly vulvovaginal and oropharyngeal candidiasis. However, the proportion of non-albicans Candida species was substantial, mainly represented by C. parapsilosis, C. tropicalis, and N. glabratus. This finding is consistent with previous studies describing an epidemiological shift toward non-albicans Candida species, especially in healthcare-associated contexts, where antimicrobial exposure, invasive devices, critical care, and improved laboratory identification may favor the detection of species with different ecological and susceptibility profiles [29,30–34]. In our study, the predominance of C. albicans in outpatient and lower-complexity settings contrasted with the greater representation of non-albicans Candida species in critical care areas, supporting the interpretation that species distribution varies according to clinical context and specimen source. Detection of emerging species in invasive samples, although infrequent, is a relevant surveillance signal. The identification of C. auris—even as a single recent isolate—aligns with regional alerts regarding spread and nosocomial transmission risk, particularly in critical care settings [35–37]. Likewise, the presence of W. anomalus in blood is consistent with reports of healthcare-associated infection and potential nosocomial events [36]. The multivariable analyses should be interpreted as exploratory and data-source specific, because the clinical/administrative and microbiological databases were not linked record by record. For clinically recorded candidemia, invasive devices, surgery, tumors, and respiratory dysfunction showed associations within the clinical/administrative database, consistent with clinical patterns described in critically ill post-surgical patients with organ dysfunction [38–41]. For clinically recorded invasive candidiasis, associations with male sex, older age, and cardiovascular comorbidity are plausible and align with cohorts in which comorbidity burden and hospital exposure influence severity and clinical outcomes [42,43]. In the microbiological isolate-level model, non-albicans isolation showed associations with candidemia, adulthood, and urinary origin, suggesting that higher-complexity scenarios and selected anatomical foci may concentrate species with less predictable susceptibility profiles [43–46]. The inverse association between short hospital stay and clinically recorded candidemia should also be interpreted cautiously and not as a protective effect. This finding likely reflects the case mix of the clinical/administrative database, in which most episodes corresponded to mucocutaneous/non-invasive candidiasis, particularly vulvovaginal candidiasis, which is commonly managed in lower-complexity or short-stay settings. Antifungal susceptibility findings should be interpreted according to the clinical source of the isolates. Because most isolates were obtained from mucocutaneous, superficial, or urogenital samples rather than invasive specimens, the pooled susceptibility results should be considered primarily as descriptive microbiological surveillance data. In mucocutaneous and urogenital candidiasis, these findings help describe species-level susceptibility patterns and azole variability, particularly the lower fluconazole performance observed in C. parapsilosis and the more limited profile observed in N. glabratus [47,48]. For invasive candidiasis, interpretation should be more cautious because the bloodstream subgroup was small and species-specific denominators were limited. Although echinocandin activity was high among predominant species and is consistent with international surveillance [29,27], these pooled data should not be used alone to guide empiric therapy for invasive candidiasis or to define institutional treatment protocols. Susceptibility percentages for species represented by fewer than 30 isolates should also be interpreted cautiously, because one or two isolates can substantially change the estimated proportion. Therefore, results for low-frequency or emerging species such as C. auris, C. dubliniensis, N. glabratus, and W. anomalus should be considered isolate-level surveillance signals rather than representative institutional resistance rates. Overall, these findings support species-level identification and isolate-level susceptibility testing in clinically significant infections, while avoiding overstatement of clinical implications [49]. The 5-fluorocytosine pattern, with predominance of non-WT classifications, should be interpreted cautiously. As EUCAST recommends ECOFF-based WT/NWT interpretation and NWT does not necessarily imply clinical failure, this may reflect surveillance artifacts related to cut-off availability, system configuration, or routine reporting rather than a direct therapeutic conclusion [50]. Given that uniformly high NWT proportions are not typically expected in multicenter studies, this finding warrants targeted verification of the reporting workflow. Overall, candidiasis in this hospital appears to involve two scenarios: a frequent, mainly outpatient mucocutaneous burden and a less frequent but clinically critical invasive burden characterized by greater etiological diversity, emerging species signals, and exploratory clinical associations. These data provide a descriptive surveillance baseline for strengthening local monitoring, microbiological confirmation, and antifungal stewardship discussions in high-complexity care settings. Conclusions This study provides a longitudinal clinical–microbiological survey of Candida infections in a single high-complexity hospital in Tolima, Colombia, during 2014–2024. The findings describe a low but sustained recorded burden of candidiasis, with predominance of C. albicans and a substantial proportion of non-albicans species, mainly C. parapsilosis and C. tropicalis. Most cases were mucocutaneous, whereas recorded invasive forms were less frequent and should be interpreted cautiously because of the low number of recorded candidemia cases and the use of separate, non-linked clinical/administrative and microbiological data sources. The susceptibility findings suggest high echinocandin activity among predominant species and variability among some non-albicans isolates. However, because susceptibility data were pooled from heterogeneous clinical specimens and several species were represented by small denominators, these results should be interpreted as descriptive isolate-level surveillance signals rather than as a standalone basis for empiric therapy or institutional treatment protocols. Overall, the study provides a local surveillance baseline that supports the need for species-level identification, isolate-level susceptibility testing, and improved microbiological confirmation in clinically significant Candida infections. Supporting information STROBE and RECORD. (DOCX) Supplementary Methods S1. Data sources and processing flow. (DOCX) Supplementary Methods S2. Antifungal susceptibility interpretation. (DOCX) Supplementary Methods S3. Multiple correspondence analysis (MCA). (DOCX) ICD-10 codes used to define candidiasis cases in the hospital database (2014–2024). (DOCX) Breakpoints/ECOFF sources and interpretation rules (CLSI/EUCAST). (DOCX) Raw WHONET MIC records and antifungal interpretation categories for Candida spp. isolates, 2022–2024. (DOCX) Variables and coding used in multiple correspondence analysis (MCA). (DOCX) Top contributing categories to MCA dimensions. (DOCX) Descriptive 5-fluorocytosine profile according to ECOFF-based WT/NWT categories. (DOCX) 26 May 2026 -->PONE-D-26-11229-->-->Clinical and microbiological epidemiology of Candida infections in a high-complexity hospital in Tolima, Colombia (2014–2024)-->-->PLOS One Dear Dr. Gonzalez, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jul 10 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Theerapong Krajaejun, M.D. Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please note that PLOS One has specific guidelines on code sharing for submissions in which author-generated code underpins the findings in the manuscript. In these cases, we expect all author-generated code to be made available without restrictions upon publication of the work. Please review our guidelines at https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse. 3. We note that you have indicated that there are restrictions to data sharing for this study. For studies involving human research participant data or other sensitive data, we encourage authors to share de-identified or anonymized data. However, when data cannot be publicly shared for ethical reasons, we allow authors to make their data sets available upon request. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Before we proceed with your manuscript, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible. Please update your Data Availability statement in the submission form accordingly. 3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Additional Editor Comments: The reviewers have evaluated this 10-year study on Candida infections in Tolima, Colombia. Key concerns include the need for clearer correlations between clinical and microbiological data, an explicit description of antifungal susceptibility testing methods, and clarification of discrepancies in candidemia incidence rates relative to national averages. Additionally, the study’s broad scope appears to limit the depth of analysis in specific areas. Overall, while the study provides valuable insights, it would benefit from greater methodological clarity and improved data analysis. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Partly Reviewer #2: Partly ********** -->2. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes Reviewer #2: No ********** -->3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: Peer Review Report: General Assessment This 10-year longitudinal study provides essential epidemiological data on Candida infections in Tolima, Colombia. The authors successfully integrated clinical and microbiological databases to characterize a sustained institutional burden. The statistical approach is robust, employing Firth-penalized regression to address the low frequency of candidemia events. The commitment to open science, demonstrated by the inclusion of Zenodo and GitHub repositories for code and data, is commendable. Major Comments for Improvement 1. Database Linkage and Clinical Correlation The authors explicitly state that the clinical and microbiological databases were analyzed separately without individual-patient level linkage. While this is a common limitation in retrospective studies, it creates a gap in correlating clinical syndromes directly with specific fungal etiologies. Interestingly, the clinical database identified 20 candidemia cases , while the microbiological database identified 23 blood isolates. Recommendation: To improve the technical soundness of the "Associated Factors" section (Page 11, Lines 177–184), the authors should clarify if the 20 candidemia cases used for the multivariable model are subset from the same patient group as the 23 blood isolates. If linkage was performed for this specific subset, it should be stated. 2. 5-Fluorocytosine (5-FC) Susceptibility Anomaly Table 3 (Page 13) shows that 99.06% (106/107) of C. albicans isolates were classified as Non-Wild Type (NWT) for 5-FC. As the authors correctly note in the Discussion (Page 18, Lines 291–296), C. albicans is typically highly susceptible to 5-FC. Attributing this to a "surveillance artifact" related to system configuration or cutoff availability is a fair assessment. Recommendation: To ensure this doesn't mislead clinical readers, the authors should specify the VITEK 2 AST card version used and confirm if WHONET expert rules were applied. If the data is an artifact, consider moving the 5-FC results to a Supplementary Table to keep the focus of Table 3 on clinically relevant susceptibilities. 3. Temporal Trend Interpretation Figure 1A (Page 28) and line 113 (Page 6) identify a peak in 2018 followed by a significant decline through 2024. In the Discussion (Page 16, Lines 241–242), the authors suggest this might reflect changes in coding or clinical criteria rather than true incidence. Recommendation: Given the administrative nature of the clinical database, the authors should explicitly state if there were changes to the Hospital Information System (HIS) or a shift from ICD-9 to ICD-10 coding during the 2018–2019 period that might have impacted case capture. 4. Statistical Transparency in Regression Models For Table 2 (Page 12), please include the final N (number of cases included) in the footer for each model (Candidemia, Invasive Candidiasis, and Non-albicans isolation). This allows reviewers to verify the ratio of events to independent variables. 5. Major Concern: Candidemia Incidence and Database Discrepancy The study reports 20 candidemia episodes identified in the clinical database and 23 blood isolates identified in the microbiological database over an 11-year period (2014–2024) across 243,013 hospitalizations. This results in an incidence rate of approximately 0.08 per 1,000 admissions, which is significantly lower than national Colombian averages (~1.96 per 1,000) and regional Latin American benchmarks (0.74 to 6.0 per 1,000 admissions). I have the following concerns and requests for clarification: • Internal Consistency: Why is there a discrepancy between the 20 clinical episodes and the 23 laboratory isolates? Does this imply that three confirmed laboratory cases were not captured in the administrative/clinical records? Please clarify if any manual validation was performed to ensure that the 20 cases used in the multivariable model represent the full clinical reality of the hospital. • Definition of "High-Complexity": The extremely low incidence (less than 2 cases per year) seems atypical for a high-complexity facility. To provide better context for these numbers, please include specific institutional data in the Methods section, such as the total number of ICU beds and the presence of specialized services (e.g., oncology, transplantation, or neonatal ICU) during the study period. • Information Bias: While the authors mention that fungal infections are underreported due to a lack of mandatory notification , the low count suggests a potential "information bias" stemming from the reliance on administrative ICD-10 coding. Please expand the Study Limitations to discuss how this specific reliance might have led to an underestimation of the invasive disease burden and how it may impact the power of the multivariable risk factor analysis. 6. Major Concern: Statistical Validity of Antifungal Susceptibility Testing (AFST) While the authors provide MIC data for 196 isolates, the sample sizes for several high-priority species are critically low, which introduces a high risk of selection bias and limits the validity of the reported resistance percentages. • Species-Level Fragility: In Table 3, susceptibility profiles for species like Nakaseomyces glabratus (n=19), Candida dubliniensis (n=4), and Wickerhamomyces anomalus (n=3) are based on numbers too small to represent institutional or regional trends. E.g. For W. anomalus, a single resistant isolate results in a reported resistance rate of 33.33%. • Bloodstream Etiology: The bloodstream subgroup (n=23) is even more fragmented, with only one C. auris isolate and two N. glabratus isolates identified. • Impact on Guidelines: The manuscript concludes that these findings support "susceptibility-guided therapy" and inform "local protocols". However, basing institutional protocols on such a limited number of isolates is statistically risky. Recommendation to Authors: Please include a clear disclaimer in the Results and Discussion stating that the susceptibility percentages for species with n < 30 (consistent with CLSI M101 guidelines for cumulative antibiograms) should be interpreted as individual case signals rather than representative institutional resistance rates. The authors should also clarify if these isolates were collected from the same patient (duplicate isolates) or represent unique infection episodes. 7. Major Revision: Clinical Relevance of Pooled Susceptibility Data In Table 3, the authors pool susceptibility results from all clinical sources—including superficial (36.62%), urogenital (33.44%), and blood (7.32%)—into a single species-level analysis. This practice significantly diminishes the clinical utility of the data for a high-complexity hospital. • Confounding by Site: The selective pressure and previous antifungal exposure for mucocutaneous isolates (often outpatient) differ fundamentally from those of invasive bloodstream isolates (often ICU-acquired). • Interpretation Bias: Clinical breakpoints (CLSI/EUCAST) are site-specific. An MIC that is considered "Susceptible" for a urinary tract infection (where drugs like fluconazole concentrate) may not be appropriate for guiding the management of candidemia. • Misleading Stewardship: By allowing superficial and urinary isolates to dominate the denominator (>70% of samples), the authors may be masking critical resistance trends in the smaller bloodstream subgroup (n=23). Recommendation to Authors: To ensure the data is "practically useful" for strengthening local surveillance, the susceptibility analysis should ideally be stratified by Invasive (Sterile Site) vs. Non-Invasive (Colonization/Superficial) samples. If the sample size is too small for stratification (as established in previous comments regarding n<10), the authors must explicitly state that the pooled data cannot be used to guide empiric therapy for invasive candidiasis and should be viewed only as a general microbiological survey. Minor Comments 1. Nomenclature Inconsistency: In Table 2 (Page 12) and Table 3 (Page 14), the term "no-albicans" is used. However, the correct scientific term "non-albicans" is used in the Abstract and Conclusion. Please standardize this to "non-albicans" throughout the manuscript. 2. Typo: Page 16, Line 248—"prioritise" is used; ensure consistent American or British English spelling throughout based on journal preference (PLOS ONE typically prefers American English: "prioritize"). Conclusion of Review: Mismatch Between Data Density and Clinical Recommendations The manuscript provides a valuable baseline for Candida diversity in Tolima, Colombia; however, there is a significant mismatch between the low density of the invasive disease data and the broadness of the clinical conclusions. • Weak Clinical Utility: The reliance on pooled susceptibility data from disparate anatomical sites (urine, skin, and blood) makes the individual case signals rather than statistically sound institutional trends. • Underestimation of Burden: The reported findings unsuitable for guiding empiric therapy in high-complexity units. • Statistical Fragility: The "non-albicans diversity" highlighted in the results is based on species counts so small (n=1 to 9) that they represent candidemia rate (0.08 per 1,000 admissions) suggests a systemic under-capture of invasive cases, which may bias the identified risk factors. Final Recommendation: The authors must significantly temper their conclusions. References to "informing local protocols" or "guiding therapy" should be replaced with a more cautious interpretation of the data as a "longitudinal microbiological survey" with recognized limitations in invasive disease capture. Reviewer #2: Abstract: Please clarify the study setting mentions 'mid-sized departments' in the background, but focuses on a 'high-complexity hospital' in the methods; please ensure these terms accurately reflect the scope your research The keywords are highly redundant (e.g., Candida, candidiasis, candidemia). Please optimize to enhance the article's discoverability Please define the acronym SIVIGILA upon its first mention in the introduction Introduction The objective of this study Please clarify the study setting. “Department” refers to a geographical region in Colombia; to avoid confusion with clinical departments, please explicitly state whether this is a single-center study. Furthermore, instead of 'high-complexity hospital', I suggest using 'tertiary care referral center' to better reflect the facility's role in the region. Statistical analysis The methodology for data management is unclear. Please revise the sentence to clearly state how data were prepared and managed before statistical analysis. For example: 'Data were managed in Microsoft Excel and analyzed using R (version 4.4.2) Results 243 013 hospitalizations were recorded seems exceptionally high for a single-center study. Please clarify whether this number represents the total hospitalizations or what? Figure 1A & B The numbers displayed on the trend line are ambiguous Results The classification of invasive candidiasis (IC) presented in Figure 2 and the Results section is inconsistent with standard clinical definitions. IC is generally categorized into candidemia, deep-seated (non-candidemic) candidiasis, or combined/disseminated infections.Currently, the distinction between 'meningitis' and 'localized' is ambiguous and does not follow recognized clinical classifications. Please revise the categorization to reflect standard definitions to ensure clinical accuracy and comparability with existing literature. Furthermore, ensure that the definition of each category is clearly stated in the Methods/Operational Definitions section. The presence of an 'Other/Unspecified' category that is nearly equal in size to the 'Localized' category is highly problematic. This indicates a substantial limitation in data granularity or diagnostic reporting The lack of cross-database linkage severely undermines the validity of the multivariable analysis. A multivariable model requires patient-level data to accurately establish independent risk factors (e.g., associating ICU stay with confirmed candidemia in the same individual). As the clinical and microbiological datasets were analyzed separately without individual-patient linkage, the study cannot establish causal or associative relationships between clinical risk factors and the presence of Candida. Consequently, any claims regarding 'established risk profiles' based on this multivariable analysis are statistically flawed and should be removed or completely re-evaluated The dataset covering 2014–2024 is substantial and holds great potential. However, the current manuscript attempts to cover too broad a scope, resulting in superficial analyses that do not fully leverage the data's potential.To enhance the scientific rigor of this work, I recommend the following: 1. Re-focus the scope: Please select one primary research question (e.g., epidemiological shifts of Candida species over the decade or a deep-dive analysis into clinical risk factors) rather than attempting a comprehensive overview that compromises depth. 2. Refine Operational Definitions: The current definitions, especially regarding IC subtypes (e.g., 'Other/Unspecified' vs 'Localized'), are not clinically standardized. Please align these with current guidelines (e.g., IDSA/ESCMID). 3. Prioritize Data Quality over Quantity: It is better to provide a robust analysis of a subset of well-linked patient data than a wide, superficial analysis of poorly linked datasets. Consider focusing the analytical part of the study only on the period where data linkage and MIC information are reliable (e.g., 2022–2024)." ********** -->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: Yes: Meiliyana Wijaya ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 26 Jun 2026 Dear Academic Editor and Reviewers, We would like to sincerely thank you for the careful evaluation of our manuscript entitled “Clinical and microbiological epidemiology of Candida infections in a high-complexity hospital in Tolima, Colombia (2014–2024)” (PONE-D-26-11229). We are grateful for the constructive comments and recommendations, which helped us improve the clarity, methodological rigor, clinical interpretation, and overall presentation of the study. We have carefully revised the manuscript in response to each comment raised by the Academic Editor and both reviewers. In particular, we clarified the relationship between the clinical/administrative and microbiological data sources, explicitly stating that they originated from the same participating hospital but were not linked record by record. We also revised the interpretation of the multivariable models, now framing them as exploratory and data-source specific rather than as definitive patient-level clinical–microbiological risk models. The Methods section was substantially revised to improve transparency regarding study design, operational definitions, data management, antifungal susceptibility testing, VITEK 2 card use, WHONET MIC exports, and the interpretation of CLSI/EUCAST-based susceptibility categories. We also refined the classification of invasive candidiasis to distinguish candidemia and deep-seated non-candidemic invasive candidiasis, while explicitly acknowledging the limitations associated with other/unspecified clinical records. The Results, Discussion, and Conclusions were also revised to provide a more cautious and balanced interpretation of the findings. We tempered claims regarding clinical risk factors, empiric therapy, and institutional treatment protocols, and reframed the study as a longitudinal clinical–microbiological survey and local surveillance baseline. In addition, we updated the tables, figures, figure legends, supplementary materials, Data Availability statement, repository information, licenses, and author metadata. The revised submission package includes a point-by-point Response to Reviewers, a marked version of the revised manuscript showing the changes made, and a clean version of the manuscript. De-identified datasets, R scripts, supporting workbooks, and reproducibility materials have been made available through Zenodo and GitHub. The authors’ ORCID identifiers have also been updated as follows: Rafael Augusto Ramírez-Trujillo: 0000-0001-9355-1765 Paula Carvajal Hernández: 0000-0002-5024-1019 Ángel González: 0000-0002-7052-7938 We believe that the revised manuscript is clearer, more methodologically transparent, and more appropriately framed in relation to the available data. We again thank the Academic Editor and reviewers for their valuable feedback and hope that the revised version adequately addresses all concerns raised during the review process. Sincerely, On behalf of all authors NOTE: ALL TEH POINT-BY-POINT RESPONSES TO THE REVIEWERS ARE FOUND IN THE RESPONSE LETTER (REBUTTAL LETTER). THERE ARE NOT DESCRIBED HERE BECAUSE THEY ARE IN A COLUMN FORMAT FOR EASIER COMPARISON. Submitted filename: Rebuttal Letter.docx 6 Jul 2026 -->PONE-D-26-11229R1-->-->Clinical and microbiological epidemiology of Candida infections in a high-complexity hospital in Tolima, Colombia (2014–2024)-->-->PLOS One Dear Dr. Gonzalez, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Aug 20 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. --> If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Theerapong Krajaejun, M.D. Academic Editor PLOS One Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments: The reviewer has requested several minor revisions to improve the clarity and interpretation of the manuscript. Please carefully address the reviewer’s comments regarding terminology, variable definitions, risk factors, and the discussion of species distribution and antifungal susceptibility. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #1: All comments have been addressed Reviewer #2: (No Response) ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes Reviewer #2: Yes ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes Reviewer #2: Yes ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: The authors have fully overhauled the interpretive framework of their paper. The revised manuscript is incredibly honest about its administrative and numeric boundaries, making it a highly accurate and useful baseline epidemiological survey for the Tolima region. No further revisions are required. Reviewer #2: The previous comments have been adequately addressed by the authors. However, I would like to provide several additional comments for further improvement: 1. Abbreviations such as CLSI and EUCAST should be written in full at first mention in the abstract, as Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2. The formatting of fungal species names should be checked carefully and made consistent throughout the manuscript. In terms such as non-albicans Candida, the prefix “non-” should not be italicized, whereas albicans Candida should be italicized. 3. The variable socioeconomic strata appears in the results table, but its definition and interpretation are not clearly explained. The authors should clarify how this variable was categorized or scored, and whether a higher score indicates better or poorer socioeconomic status. If this variable is not further analyzed or discussed, it may be better to exclude it. 4. The section on predisposing factors should be removed or substantially revised, as these factors are not clearly included in the operational definitions and are not well explained in the discussion. For example, the term “predisposing medication” is too vague and should specify the type of medication. The discussion of short hospital stay is also unclear, particularly since most cases appear to involve mucocutaneous candidiasis, especially vulvovaginal candidiasis. 5. The discussion of Candida species distribution should be expanded. The authors should further explore the predominance of Candida albicans or non-albicans Candida species and compare these findings with previous studies. 6. The discussion of antifungal susceptibility requires clearer framing. Although many isolates appear to be susceptible to echinocandins, the discussion should not focus too heavily on invasive candidiasis if most isolates were not obtained from invasive cases. The authors should clearly distinguish the interpretation of antifungal susceptibility findings between invasive candidiasis and mucocutaneous candidiasis to avoid overstating the clinical implications. ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. --> 9 Jul 2026 Dear editors and reviewers, All the comments and suggestions were responded Point-by-point; you can find these responses in the rebuttal letter. This information was not responded here because they are in a column format. All the best, Submitted filename: Rebuttal Letter_R2.docx 13 Jul 2026 Clinical and microbiological epidemiology of Candida infections in a high-complexity hospital in Tolima, Colombia (2014–2024) PONE-D-26-11229R2 Dear Dr. Gonzalez, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Theerapong Krajaejun, M.D. Academic Editor PLOS One Additional Editor Comments (optional): The authors have adequately addressed the reviewers’ comments, and the manuscript has been substantially improved. The study provides valuable epidemiological insights into Candida infections in Tolima, Colombia, and represents a meaningful contribution to the regional literature on candidiasis. Reviewers' comments: PONE-D-26-11229R2 PLOS One Dear Dr. Gonzalez, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Theerapong Krajaejun Academic Editor PLOS One